Views: 148 Downloads: 21

Mohsen Tahmasbi Qarabi , Seyed Nematollah Jazayeri , Parvin Kheradmand , Maryam Seyedtabib

Abstract

CD10 is expressed as a cell surface antigen in acute lymphoblastic leukemias. Few and conflicting studies have been conducted to determine the role of CD10 in thyroid cancer prognosis. Therefore, the present study was conducted with the aim of investigating the expression of CD10 in the differentiation of benign and malignant thyroid tumors. In this retrospective study, 80 malignant tumors and 25 benign thyroid blockes were collected from the histopathological laboratory of Golestan Hospital in Ahvaz between 2021 and 2023. The specific staining for the CD10 marker was performed using an immunohistochemical method using paraffin blocks. In the present study, 87.5% of malignant cases showed positive CD10 expression and 12.5% of remaining cases showed negative CD10 expression, while 44% of benign cases showed positive CD10 expression and 56% of remaining cases showed negative CD10 expression showed. The results showed that there is a statistically significant relationship between the pathological tumor type and CD10 expression (P < 0.0001). According to the results, the highest positive percentage of CD10 expression was related to the type of follicular papillary malignant tumor with a frequency of 96%. Finally, in the present study, there was no significant correlation between the expression intensity of the CD10 marker and demographic and clinicopathological characteristics (p > 0.05). Overall, the present study showed that CD10 marker can be used to differentiate between benign and malignant thyroid tumors, but it is not associated with prognosis.